Indian HIV drugs market forecast to reach $54 million by 2014
The market for HIV drugs in India is expected to reach 454 million by 2014, according to a new report from TechNavio. One of the key factors contributing to this market growth is the increasing prevalence of HIV in India and the longer life expectancy of HIV patients.
The HIV drugs market in India has also been witnessing the development of immune-based therapies for HIV. However, the inadequate availability of physicians with a specialization in HIV treatment could be a challenge to the growth of this market.
The report focuses on India and covers healthcare institutions, over the counter/retail, and HIV rehabilitation centers. The report analyzes the current HIV Drugs market landscape and its growth prospects. It also includes a discussion of the key vendors operating in this market. Key vendors dominating this market include domestic drugmakers Cipla, Hetero Drugs’ Ranbaxy Laboratories and Zydus Cadila Healthcare.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze